AU2011222452B2 - Stabilized alpha-galactosidase and uses thereof - Google Patents

Stabilized alpha-galactosidase and uses thereof Download PDF

Info

Publication number
AU2011222452B2
AU2011222452B2 AU2011222452A AU2011222452A AU2011222452B2 AU 2011222452 B2 AU2011222452 B2 AU 2011222452B2 AU 2011222452 A AU2011222452 A AU 2011222452A AU 2011222452 A AU2011222452 A AU 2011222452A AU 2011222452 B2 AU2011222452 B2 AU 2011222452B2
Authority
AU
Australia
Prior art keywords
gal
galactosidase
activity
protein structure
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011222452A
Other languages
English (en)
Other versions
AU2011222452A1 (en
Inventor
Yaniv Azulay
Tehila Ben-Moshe
Tali Kizhner
Ilya Ruderfer
Yoseph Shaaltiel
Talia Shekhter
Avidor Shulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protalix Ltd
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of AU2011222452A1 publication Critical patent/AU2011222452A1/en
Application granted granted Critical
Publication of AU2011222452B2 publication Critical patent/AU2011222452B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2011222452A 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof Active AU2011222452B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
US61/309,487 2010-03-02
AUPCT/IL2010/000956 2010-11-17
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20
US61/434,499 2011-01-20
US61/434,503 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (2)

Publication Number Publication Date
AU2011222452A1 AU2011222452A1 (en) 2012-09-27
AU2011222452B2 true AU2011222452B2 (en) 2015-09-03

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011222452A Active AU2011222452B2 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Country Status (23)

Country Link
EP (3) EP3088514B1 (enExample)
JP (2) JP5758920B2 (enExample)
KR (1) KR101928403B1 (enExample)
CN (1) CN102933707B (enExample)
AU (1) AU2011222452B2 (enExample)
BR (2) BR112012022029B1 (enExample)
CA (1) CA2791461C (enExample)
DK (1) DK2865751T3 (enExample)
ES (2) ES2606532T3 (enExample)
FI (1) FIC20230032I1 (enExample)
FR (1) FR23C1041I2 (enExample)
HR (1) HRP20200428T1 (enExample)
HU (2) HUE030959T2 (enExample)
IL (2) IL221741A (enExample)
IN (1) IN2012MN02262A (enExample)
NL (1) NL301249I2 (enExample)
NO (1) NO2023041I1 (enExample)
NZ (2) NZ602317A (enExample)
PL (1) PL2865751T3 (enExample)
SG (2) SG10201502609QA (enExample)
SI (1) SI2865751T1 (enExample)
WO (1) WO2011107990A1 (enExample)
ZA (1) ZA201206725B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用
JP5913372B2 (ja) * 2011-01-20 2016-04-27 プロタリクス リミテッド 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
KR102702200B1 (ko) 2014-12-22 2024-09-02 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
PL3271453T3 (pl) 2015-03-17 2022-01-17 eleva GmbH Glikozylowane białka lizosomowe, sposób wytwarzania i zastosowania
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
NZ755725A (en) * 2017-01-05 2023-06-30 Protalix Ltd Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
US11517613B2 (en) * 2017-06-07 2022-12-06 Amano Enzyme Inc. Lactase bulk powder and lactase preparation
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
AR121457A1 (es) * 2020-02-28 2022-06-08 Codexis Inc VARIANTES DE a-GALACTOSIDASA HUMANA
JP2023548496A (ja) 2020-11-03 2023-11-17 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) * 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935336B2 (en) * 2005-11-18 2011-05-03 Tokyo Metropolitan Organization For Medical Research Highly functional enzyme having α-galactosidase activity

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DE69839563D1 (de) * 1997-09-05 2008-07-10 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
DE60022336T2 (de) 1999-04-02 2006-06-22 Ajinomoto Co., Inc. Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
EP1523548B1 (en) 2002-05-15 2009-12-30 Agricultural Research Organization Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
PL1877099T3 (pl) * 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935336B2 (en) * 2005-11-18 2011-05-03 Tokyo Metropolitan Organization For Medical Research Highly functional enzyme having α-galactosidase activity

Also Published As

Publication number Publication date
KR20130056216A (ko) 2013-05-29
IL253249A (en) 2019-08-29
EP3088514B1 (en) 2018-11-28
EP2865751A1 (en) 2015-04-29
CN102933707A (zh) 2013-02-13
HUE030959T2 (en) 2017-06-28
WO2011107990A1 (en) 2011-09-09
HRP20200428T1 (hr) 2020-06-12
RU2012141651A (ru) 2014-04-10
JP2014237694A (ja) 2014-12-18
CA2791461A1 (en) 2011-09-09
DK2865751T3 (en) 2017-01-09
BR112012022029B1 (pt) 2022-10-11
SG183558A1 (en) 2012-10-30
FR23C1041I2 (fr) 2024-08-02
IL253249B (en) 2020-08-31
HK1180720A1 (en) 2013-10-25
SG10201502609QA (en) 2015-05-28
EP2542675A1 (en) 2013-01-09
NL301249I1 (enExample) 2023-11-08
JP5871999B2 (ja) 2016-03-01
NZ623294A (en) 2015-10-30
EP3088514A1 (en) 2016-11-02
NZ602317A (en) 2014-04-30
NO2023041I1 (no) 2023-11-01
EP2865751B1 (en) 2016-09-14
NL301249I2 (nl) 2023-12-14
EP2542675B1 (en) 2014-12-17
FIC20230032I1 (fi) 2023-11-02
CN102933707B (zh) 2015-09-30
HUS2300038I1 (hu) 2023-11-28
ES2708843T3 (es) 2019-04-11
ES2606532T3 (es) 2017-03-24
PL2865751T3 (pl) 2017-03-31
RU2604795C2 (ru) 2016-12-10
KR101928403B1 (ko) 2018-12-14
ZA201206725B (en) 2013-06-26
JP2013520986A (ja) 2013-06-10
SI2865751T1 (sl) 2017-01-31
BR112012022029A2 (pt) 2021-05-18
JP5758920B2 (ja) 2015-08-05
BR122014021216A2 (pt) 2021-06-01
FR23C1041I1 (enExample) 2023-12-29
IL221741A (en) 2017-07-31
IN2012MN02262A (enExample) 2015-06-12
CA2791461C (en) 2019-10-22
AU2011222452A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
AU2011222452B2 (en) Stabilized alpha-galactosidase and uses thereof
US12385026B2 (en) Stabilized alpha-galactosidase and uses thereof
KR101955054B1 (ko) 리소좀 축적증의 개선된 치료를 위해 재조합 리소좀 효소상에 표적화 펩티드를 커플링시키는 방법
EP2542674B1 (en) Glucocerebrosidase multimers and uses thereof
HK1180720B (en) Stabilized alpha-galactosidase and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)